Elsevier

Cytokine

Volume 2, Issue 6, November 1990, Pages 402-406
Cytokine

Original contributions
Infusion of tumor necrosis factor (TNF) causes an increase in circulating TNF-binding protein in humans

https://doi.org/10.1016/1043-4666(90)90048-XGet rights and content

Abstract

Serum samples from cancer patients receiving intravenous infusions of recombinant tumor necrosis factor (rTNF) and recombinant interferon-γ (rIFN-γ) were analyzed for TNF and the TNF-binding protein (TNF-BP). TNF-BP is a soluble fragment of the transmembrane TNF receptor with antagonistic effects to TNF and is released by proteolytic cleavage of the receptor. During a 60-min infusion of rTNF, peak serum levels of rTNF were observed after 30 to 60 min and a transient increase of circulating TNF-BP was observed with peak levels between 30 and 120 min. Injection of IFN-γ alone did not affect the levels of TNF and TNF-BP. Thus administration of rTNF leads to release into the circulation of TNF-BP, which may modulate both systemic and local effects of TNF and influence its therapeutic efficacy.

References (29)

  • PF Piguet et al.

    Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs.-host disease

    J Exp Med

    (1987)
  • C Peetre et al.

    A tumor necrosis factor binding protein is present in human biological fluids

    Eur J Haematol

    (1988)
  • P Seckinger et al.

    A human inhibitor for tumor necrosis factor

    J Exp Med

    (1988)
  • I Olsson et al.

    Isolation and characterization of a tumor necrosis factor binding protein from urine

    Eur J Haematol

    (1989)
  • Cited by (0)

    View full text